PMID- 20730701
OWN - NLM
STAT- MEDLINE
DCOM- 20110202
LR  - 20100823
IS  - 2040-3429 (Electronic)
IS  - 1472-4472 (Linking)
VI  - 11
IP  - 9
DP  - 2010 Sep
TI  - M-118, a novel, low-molecular-weight heparin for the potential treatment of 
      cardiovascular disorders.
PG  - 1059-65
AB  - Safe inhibition of thrombosis is a key therapeutic strategy in modern 
      cardiovascular medicine, and both unfractionated heparin (UFH) and 
      low-molecular-weight heparin (LMWH) are commonly used in clinical practice. 
      However, both have several drawbacks, such as the unpredictable pharmacokinetics 
      of UFH and the non-reversibility of LMWH. M-118, being developed by Momenta 
      Pharmaceuticals Inc, is a novel LMWH that has been engineered to overcome the 
      drawbacks of UFH and currently available LMWHs, while maintaining their 
      beneficial attributes. In preclinical studies and phase I clinical trials, M-118 
      demonstrated potent activity against thrombin and Factor Xa, which could be 
      reversed with protamine; M-118 also demonstrated a high and predictable 
      bioavailability, and a short half-life. Promising results were observed in a 
      phase II clinical trial in patients undergoing coronary interventions, although 
      phase III clinical trials are required to establish the role for M-118 in 
      contemporary medicine.
FAU - Shah, Hriday
AU  - Shah H
AD  - University of Michigan, Division of Cardiovascular Medicine, 2A394, 1500 East 
      Medical Center Drive, Ann Arbor, MI 48109-5853, USA.
FAU - Gurm, Hitinder S
AU  - Gurm HS
LA  - eng
PT  - Journal Article
PL  - England
TA  - Curr Opin Investig Drugs
JT  - Current opinion in investigational drugs (London, England : 2000)
JID - 100965718
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 0 (M-118 compound)
RN  - EC 3.4.21.5 (Thrombin)
SB  - IM
MH  - Animals
MH  - Anticoagulants/adverse effects/pharmacokinetics/pharmacology/therapeutic use
MH  - Cardiovascular Diseases/*drug therapy
MH  - Clinical Trials as Topic
MH  - Dogs
MH  - Drug Evaluation, Preclinical
MH  - Heparin, Low-Molecular-Weight/adverse 
      effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Knockout
MH  - Rabbits
MH  - Rats
MH  - Thrombin/antagonists & inhibitors
MH  - Thrombosis/drug therapy
EDAT- 2010/08/24 06:00
MHDA- 2011/02/03 06:00
CRDT- 2010/08/24 06:00
PHST- 2010/08/24 06:00 [entrez]
PHST- 2010/08/24 06:00 [pubmed]
PHST- 2011/02/03 06:00 [medline]
PST - ppublish
SO  - Curr Opin Investig Drugs. 2010 Sep;11(9):1059-65.